Clinical evaluation of autonomous, unsupervised planning integrated in MR-guided radiotherapy for prostate cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2022
Historique:
received: 15 10 2021
revised: 04 01 2022
accepted: 25 01 2022
pubmed: 9 2 2022
medline: 8 4 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

This retrospective study aimed at clinical evaluation of autonomous radiotherapy planning for ten prostate cancer cases, including organ-at-risk/target contouring and treatment planning. Five experts scored the clinical acceptability of each step using a 4-level Likert-scale resulting in 78%, 66% and 90% acceptance. For 6/10 patients the entire workflow was considered acceptable.

Identifiants

pubmed: 35134447
pii: S0167-8140(22)00062-7
doi: 10.1016/j.radonc.2022.01.036
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-233

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta AB (Stockholm, Sweden), TheraPanacea (Paris, France), Philips GmbH (Best, The Netherlands); Dr. Sennewald Medizintechnik GmbH (München, Germany), PTW Freiburg (Germany).

Auteurs

Luise A Künzel (LA)

Section for Biomedical Physic, Department of Radiation Oncology, University Hospital Tübingen, Germany.

Marcel Nachbar (M)

Section for Biomedical Physic, Department of Radiation Oncology, University Hospital Tübingen, Germany.

Markus Hagmüller (M)

Section for Biomedical Physic, Department of Radiation Oncology, University Hospital Tübingen, Germany.

Cihan Gani (C)

Department of Radiation Oncology, University Hospital Tübingen, Germany.

Simon Boeke (S)

Department of Radiation Oncology, University Hospital Tübingen, Germany.

Daniel Wegener (D)

Department of Radiation Oncology, University Hospital Tübingen, Germany.

Frank Paulsen (F)

Department of Radiation Oncology, University Hospital Tübingen, Germany.

Daniel Zips (D)

Department of Radiation Oncology, University Hospital Tübingen, Germany; German Cancer Consortium (DKTK), partner site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Daniela Thorwarth (D)

Section for Biomedical Physic, Department of Radiation Oncology, University Hospital Tübingen, Germany; German Cancer Consortium (DKTK), partner site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: Daniela.thorwarth@med.uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH